Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition

Erik A. Taylor; Eve Donnelly; Xiaomei Yao; Mark L. Johnson; Sarah K. Amugongo; Donald B. Kimmel; Nancy E. Lane

doi:10.1007/s00223-019-00634-w

Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition

Erik A. Taylor, Eve Donnelly, Xiaomei Yao, Mark L. Johnson, Sarah K. Amugongo, Donald B. Kimmel, Nancy E. Lane

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Anti-resorptive and anabolic treatments can be used sequentially to treat osteoporosis, but their effects on bone composition are incompletely understood. Osteocytes may influence bone tissue composition with sequential therapies because bisphosphonates diffuse into the canalicular network and anabolic treatments increase osteocyte lacunar size. Cortical bone composition of osteopenic, ovariectomized (OVX) rats was compared to that of Sham-operated rats and OVX rats given monotherapy or sequential regimens of single approved anti-osteoporosis medications. Adult female Sprague–Dawley rats were OVX (N = 37) or Sham–OVXd (N = 6). After 2 months, seven groups of OVX rats were given three consecutive 3-month periods of treatment with vehicle (V), h-PTH (1–34) (P), alendronate (A), or raloxifene (R), using the following orders: VVV, PVV, RRR, RPR, AAA, AVA, and APA. Compositional properties around osteocyte lacunae of the left tibial cortex were assessed from Raman spectra in perilacunar and non-perilacunar bone matrix regions. Sequential treatments involving parathyroid hormone (PTH) caused lower mean collagen maturity relative to monotherapies. Mean mineral:matrix ratio was 2.2% greater, mean collagen maturity was 1.4% greater, and mean carbonate:phosphate ratio was 2.2% lower in the perilacunar than in the non-perilacunar bone matrix region (all P < 0.05). These data demonstrate cortical bone tissue composition differences around osteocytes caused by sequential treatment with anti-osteoporosis medications. We speculate that the region-specific differences demonstrate the ability of osteocytes to alter bone tissue composition adjacent to lacunae.

Original language	English (US)
Pages (from-to)	303-314
Number of pages	12
Journal	Calcified Tissue International
Volume	106
Issue number	3
DOIs	https://doi.org/10.1007/s00223-019-00634-w
State	Published - Mar 1 2020
Externally published	Yes

Bibliographical note

Funding Information:
We acknowledge Lynn Johnson, PhD, of the Cornell Statistical Consulting Unit for assistance with statistical analysis. This work was funded by National Institutes of Health Grants #?s R01 AR043052-07, 1 P50 AR03043, P50 AR060752NIH to NEL; The Endowment for Aging Research at UC Davis to NEL; and the Center for Musculoskeletal Health at UC Davis.

Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.

Keywords

Carbonate:phosphate
Collagen maturity
Crystallinity
Mineral:matrix
Osteocyte
Perilacunar
Raman spectroscopy

Publisher link

10.1007/s00223-019-00634-w

Find It

Find It at U of M Libraries

Cite this

Taylor, E. A., Donnelly, E., Yao, X., Johnson, M. L., Amugongo, S. K., Kimmel, D. B., & Lane, N. E. (2020). Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition. Calcified Tissue International, 106(3), 303-314. https://doi.org/10.1007/s00223-019-00634-w

Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition. / Taylor, Erik A.; Donnelly, Eve; Yao, Xiaomei et al.
In: Calcified Tissue International, Vol. 106, No. 3, 01.03.2020, p. 303-314.

Research output: Contribution to journal › Article › peer-review

@article{e4db960e9b5a4c199d686e40eef47714,

title = "Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition",

abstract = "Anti-resorptive and anabolic treatments can be used sequentially to treat osteoporosis, but their effects on bone composition are incompletely understood. Osteocytes may influence bone tissue composition with sequential therapies because bisphosphonates diffuse into the canalicular network and anabolic treatments increase osteocyte lacunar size. Cortical bone composition of osteopenic, ovariectomized (OVX) rats was compared to that of Sham-operated rats and OVX rats given monotherapy or sequential regimens of single approved anti-osteoporosis medications. Adult female Sprague–Dawley rats were OVX (N = 37) or Sham–OVXd (N = 6). After 2 months, seven groups of OVX rats were given three consecutive 3-month periods of treatment with vehicle (V), h-PTH (1–34) (P), alendronate (A), or raloxifene (R), using the following orders: VVV, PVV, RRR, RPR, AAA, AVA, and APA. Compositional properties around osteocyte lacunae of the left tibial cortex were assessed from Raman spectra in perilacunar and non-perilacunar bone matrix regions. Sequential treatments involving parathyroid hormone (PTH) caused lower mean collagen maturity relative to monotherapies. Mean mineral:matrix ratio was 2.2% greater, mean collagen maturity was 1.4% greater, and mean carbonate:phosphate ratio was 2.2% lower in the perilacunar than in the non-perilacunar bone matrix region (all P < 0.05). These data demonstrate cortical bone tissue composition differences around osteocytes caused by sequential treatment with anti-osteoporosis medications. We speculate that the region-specific differences demonstrate the ability of osteocytes to alter bone tissue composition adjacent to lacunae.",

keywords = "Carbonate:phosphate, Collagen maturity, Crystallinity, Mineral:matrix, Osteocyte, Perilacunar, Raman spectroscopy",

author = "Taylor, {Erik A.} and Eve Donnelly and Xiaomei Yao and Johnson, {Mark L.} and Amugongo, {Sarah K.} and Kimmel, {Donald B.} and Lane, {Nancy E.}",

note = "Funding Information: We acknowledge Lynn Johnson, PhD, of the Cornell Statistical Consulting Unit for assistance with statistical analysis. This work was funded by National Institutes of Health Grants #?s R01 AR043052-07, 1 P50 AR03043, P50 AR060752NIH to NEL; The Endowment for Aging Research at UC Davis to NEL; and the Center for Musculoskeletal Health at UC Davis. Publisher Copyright: {\textcopyright} 2019, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2020",

month = mar,

day = "1",

doi = "10.1007/s00223-019-00634-w",

language = "English (US)",

volume = "106",

pages = "303--314",

journal = "Calcified Tissue International",

issn = "0171-967X",

publisher = "Springer",

number = "3",

}

TY - JOUR

T1 - Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition

AU - Taylor, Erik A.

AU - Donnelly, Eve

AU - Yao, Xiaomei

AU - Johnson, Mark L.

AU - Amugongo, Sarah K.

AU - Kimmel, Donald B.

AU - Lane, Nancy E.

N1 - Funding Information: We acknowledge Lynn Johnson, PhD, of the Cornell Statistical Consulting Unit for assistance with statistical analysis. This work was funded by National Institutes of Health Grants #?s R01 AR043052-07, 1 P50 AR03043, P50 AR060752NIH to NEL; The Endowment for Aging Research at UC Davis to NEL; and the Center for Musculoskeletal Health at UC Davis. Publisher Copyright: © 2019, Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Anti-resorptive and anabolic treatments can be used sequentially to treat osteoporosis, but their effects on bone composition are incompletely understood. Osteocytes may influence bone tissue composition with sequential therapies because bisphosphonates diffuse into the canalicular network and anabolic treatments increase osteocyte lacunar size. Cortical bone composition of osteopenic, ovariectomized (OVX) rats was compared to that of Sham-operated rats and OVX rats given monotherapy or sequential regimens of single approved anti-osteoporosis medications. Adult female Sprague–Dawley rats were OVX (N = 37) or Sham–OVXd (N = 6). After 2 months, seven groups of OVX rats were given three consecutive 3-month periods of treatment with vehicle (V), h-PTH (1–34) (P), alendronate (A), or raloxifene (R), using the following orders: VVV, PVV, RRR, RPR, AAA, AVA, and APA. Compositional properties around osteocyte lacunae of the left tibial cortex were assessed from Raman spectra in perilacunar and non-perilacunar bone matrix regions. Sequential treatments involving parathyroid hormone (PTH) caused lower mean collagen maturity relative to monotherapies. Mean mineral:matrix ratio was 2.2% greater, mean collagen maturity was 1.4% greater, and mean carbonate:phosphate ratio was 2.2% lower in the perilacunar than in the non-perilacunar bone matrix region (all P < 0.05). These data demonstrate cortical bone tissue composition differences around osteocytes caused by sequential treatment with anti-osteoporosis medications. We speculate that the region-specific differences demonstrate the ability of osteocytes to alter bone tissue composition adjacent to lacunae.

AB - Anti-resorptive and anabolic treatments can be used sequentially to treat osteoporosis, but their effects on bone composition are incompletely understood. Osteocytes may influence bone tissue composition with sequential therapies because bisphosphonates diffuse into the canalicular network and anabolic treatments increase osteocyte lacunar size. Cortical bone composition of osteopenic, ovariectomized (OVX) rats was compared to that of Sham-operated rats and OVX rats given monotherapy or sequential regimens of single approved anti-osteoporosis medications. Adult female Sprague–Dawley rats were OVX (N = 37) or Sham–OVXd (N = 6). After 2 months, seven groups of OVX rats were given three consecutive 3-month periods of treatment with vehicle (V), h-PTH (1–34) (P), alendronate (A), or raloxifene (R), using the following orders: VVV, PVV, RRR, RPR, AAA, AVA, and APA. Compositional properties around osteocyte lacunae of the left tibial cortex were assessed from Raman spectra in perilacunar and non-perilacunar bone matrix regions. Sequential treatments involving parathyroid hormone (PTH) caused lower mean collagen maturity relative to monotherapies. Mean mineral:matrix ratio was 2.2% greater, mean collagen maturity was 1.4% greater, and mean carbonate:phosphate ratio was 2.2% lower in the perilacunar than in the non-perilacunar bone matrix region (all P < 0.05). These data demonstrate cortical bone tissue composition differences around osteocytes caused by sequential treatment with anti-osteoporosis medications. We speculate that the region-specific differences demonstrate the ability of osteocytes to alter bone tissue composition adjacent to lacunae.

KW - Carbonate:phosphate

KW - Collagen maturity

KW - Crystallinity

KW - Mineral:matrix

KW - Osteocyte

KW - Perilacunar

KW - Raman spectroscopy

UR - http://www.scopus.com/inward/record.url?scp=85075671153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075671153&partnerID=8YFLogxK

U2 - 10.1007/s00223-019-00634-w

DO - 10.1007/s00223-019-00634-w

M3 - Article

C2 - 31784772

AN - SCOPUS:85075671153

SN - 0171-967X

VL - 106

SP - 303

EP - 314

JO - Calcified Tissue International

JF - Calcified Tissue International

IS - 3

ER -

Sequential Treatment of Estrogen Deficient, Osteopenic Rats with Alendronate, Parathyroid Hormone (1–34), or Raloxifene Alters Cortical Bone Mineral and Matrix Composition

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this